279 related articles for article (PubMed ID: 9737686)
1. The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms.
Zhang W; Ohnishi K; Shigeno K; Fujisawa S; Naito K; Nakamura S; Takeshita K; Takeshita A; Ohno R
Leukemia; 1998 Sep; 12(9):1383-91. PubMed ID: 9737686
[TBL] [Abstract][Full Text] [Related]
2. Arsenic trioxide (As2O3)-induced apoptosis and differentiation in retinoic acid-resistant acute promyelocytic leukemia model in hGM-CSF-producing transgenic SCID mice.
Kinjo K; Kizaki M; Muto A; Fukuchi Y; Umezawa A; Yamato K; Nishihara T; Hata J; Ito M; Ueyama Y; Ikeda Y
Leukemia; 2000 Mar; 14(3):431-8. PubMed ID: 10720138
[TBL] [Abstract][Full Text] [Related]
3. Effect of arsenic trioxide on viability, proliferation, and apoptosis in human megakaryocytic leukemia cell lines.
Lu M; Levin J; Sulpice E; Sequeira-Le Grand A; Alemany M; Caen JP; Han ZC
Exp Hematol; 1999 May; 27(5):845-52. PubMed ID: 10340400
[TBL] [Abstract][Full Text] [Related]
4. Dual effects of arsenic trioxide (As2O3) on non-acute promyelocytic leukaemia myeloid cell lines: induction of apoptosis and inhibition of proliferation.
Rojewski MT; Baldus C; Knauf W; Thiel E; Schrezenmeier H
Br J Haematol; 2002 Mar; 116(3):555-63. PubMed ID: 11849211
[TBL] [Abstract][Full Text] [Related]
5. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner.
Wang ZG; Rivi R; Delva L; König A; Scheinberg DA; Gambacorti-Passerini C; Gabrilove JL; Warrell RP; Pandolfi PP
Blood; 1998 Sep; 92(5):1497-504. PubMed ID: 9716575
[TBL] [Abstract][Full Text] [Related]
6. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations.
Zhu XH; Shen YL; Jing YK; Cai X; Jia PM; Huang Y; Tang W; Shi GY; Sun YP; Dai J; Wang ZY; Chen SJ; Zhang TD; Waxman S; Chen Z; Chen GQ
J Natl Cancer Inst; 1999 May; 91(9):772-8. PubMed ID: 10328107
[TBL] [Abstract][Full Text] [Related]
7. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins.
Chen GQ; Zhu J; Shi XG; Ni JH; Zhong HJ; Si GY; Jin XL; Tang W; Li XS; Xong SM; Shen ZX; Sun GL; Ma J; Zhang P; Zhang TD; Gazin C; Naoe T; Chen SJ; Wang ZY; Chen Z
Blood; 1996 Aug; 88(3):1052-61. PubMed ID: 8704214
[TBL] [Abstract][Full Text] [Related]
8. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells.
Chen GQ; Shi XG; Tang W; Xiong SM; Zhu J; Cai X; Han ZG; Ni JH; Shi GY; Jia PM; Liu MM; He KL; Niu C; Ma J; Zhang P; Zhang TD; Paul P; Naoe T; Kitamura K; Miller W; Waxman S; Wang ZY; de The H; Chen SJ; Chen Z
Blood; 1997 May; 89(9):3345-53. PubMed ID: 9129041
[TBL] [Abstract][Full Text] [Related]
9. MicroRNAs contribute to promyelocyte apoptosis in As2O3-treated APL cells.
Liang H; Li X; Wang L; Yu S; Xu Z; Gu Y; Pan Z; Li T; Hu M; Cui H; Liu X; Zhang Y; Xu C; Guo R; Lu Y; Yang B; Shan H
Cell Physiol Biochem; 2013; 32(6):1818-29. PubMed ID: 24356076
[TBL] [Abstract][Full Text] [Related]
10. Phenylarsine oxide (PAO) more intensely induces apoptosis in acute promyelocytic leukemia and As2O3-resistant APL cell lines than As2O3 by activating the mitochondrial pathway.
Sahara N; Takeshita A; Kobayashi M; Shigeno K; Nakamura S; Shinjo K; Naito K; Maekawa M; Horii T; Ohnishi K; Kitamura K; Naoe T; Hayash H; Ohno R
Leuk Lymphoma; 2004 May; 45(5):987-95. PubMed ID: 15291359
[TBL] [Abstract][Full Text] [Related]
11. Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia.
Cai X; Shen YL; Zhu Q; Jia PM; Yu Y; Zhou L; Huang Y; Zhang JW; Xiong SM; Chen SJ; Wang ZY; Chen Z; Chen GQ
Leukemia; 2000 Feb; 14(2):262-70. PubMed ID: 10673743
[TBL] [Abstract][Full Text] [Related]
12. The effects of arsenic trioxide (As2O3) on human megakaryocytic leukemia cell lines. With a comparison of its effects on other cell lineages.
Alemany M; Levin J
Leuk Lymphoma; 2000 Jun; 38(1-2):153-63. PubMed ID: 10811458
[TBL] [Abstract][Full Text] [Related]
13. Effects of arsenic trioxide (As2O3) on leukemic cells from patients with non-M3 acute myelogenous leukemia: studies of cytotoxicity, apoptosis and the pattern of resistance.
Lehmann S; Bengtzen S; Paul A; Christensson B; Paul C
Eur J Haematol; 2001 Jun; 66(6):357-64. PubMed ID: 11488934
[TBL] [Abstract][Full Text] [Related]
14. Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines.
König A; Wrazel L; Warrell RP; Rivi R; Pandolfi PP; Jakubowski A; Gabrilove JL
Blood; 1997 Jul; 90(2):562-70. PubMed ID: 9226155
[TBL] [Abstract][Full Text] [Related]
15. Arsenic trioxide induces apoptosis in leukemia/lymphoma cell lines via the CD95/CD95L system.
Zhu J; Okumura H; Ohtake S; Nakamura S; Nakao S
Oncol Rep; 2003; 10(3):705-9. PubMed ID: 12684647
[TBL] [Abstract][Full Text] [Related]
16. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system.
Dai J; Weinberg RS; Waxman S; Jing Y
Blood; 1999 Jan; 93(1):268-77. PubMed ID: 9864170
[TBL] [Abstract][Full Text] [Related]
17. Treatment of acute promyelocytic leukemia with arsenic compounds: in vitro and in vivo studies.
Chen Z; Chen GQ; Shen ZX; Chen SJ; Wang ZY
Semin Hematol; 2001 Jan; 38(1):26-36. PubMed ID: 11172537
[TBL] [Abstract][Full Text] [Related]
18. Involvement of CD95-independent caspase 8 activation in arsenic trioxide-induced apoptosis.
Kitamura K; Minami Y; Yamamoto K; Akao Y; Kiyoi H; Saito H; Naoe T
Leukemia; 2000 Oct; 14(10):1743-50. PubMed ID: 11021749
[TBL] [Abstract][Full Text] [Related]
19. [Preliminary study on the arsenic trioxide-induced NB4 cell apoptosis and its molecular mechanisms].
Chen G; Zhu J; Shi X; Zhong H; Liu W; Jin X; Tang W; Li X; Ni J; Xiong S; Shen Z; Ma J; Zhang P; Zhang T; Claude G; Chen S; Chen L; Wang Z
Zhonghua Xue Ye Xue Za Zhi; 1997 Jan; 18(1):25-8. PubMed ID: 15622746
[TBL] [Abstract][Full Text] [Related]
20. Antitumor efficacy of DMSA modified Fe3O4 magnetic nanoparticles combined with arsenic trioxide and adriamycin in Raji cells.
Cai X; Cai X; Wang C; Chen B; Hua W; Shen F; Yu L; He Z; Shi Y; Chen Y; Xia G; Bao W; Zhang Y; Wang X
J Biomed Nanotechnol; 2014 Feb; 10(2):251-61. PubMed ID: 24738333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
